Cortical Stimulation for Movement Disorders
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.
Will I have to stop taking my current medications?
The trial requires that you do not take tricyclic antidepressants or certain CNS (central nervous system) active drugs that are considered a strong potential hazard. If you are on these medications, you may need to stop them to participate.
Is cortical stimulation for movement disorders generally safe in humans?
Research shows that transcranial direct current stimulation (tDCS) is generally safe in humans, with no reports of serious adverse effects in over 33,200 sessions. Common mild side effects include itching, tingling, and headache, but these are not significantly different from placebo treatments.12345
How does the treatment 'Cortical Stimulation for Movement Disorders' differ from other treatments for movement disorders?
This treatment is unique because it uses noninvasive brain stimulation techniques like transcranial direct current stimulation (tDCS) and repetitive transcranial magnetic stimulation (rTMS) to alter brain activity and connectivity, potentially improving movement control. Unlike traditional drug therapies, these methods directly target brain regions involved in movement, offering a novel approach for managing movement disorders.678910
What data supports the effectiveness of the treatment for movement disorders?
Who Is on the Research Team?
Biyu He, MD
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
This trial is for English-speaking healthy individuals or patients with psychogenic movement disorders (PMD) or psychogenic non-epileptic seizures (PNES), confirmed by a specialist. Participants should not expect treatment changes for 3-6 months and must not have significant neurological issues, chronic conditions, head trauma, substance abuse, certain psychiatric conditions, pregnancy, metal in the body, be taking specific medications or have inflammatory/autoimmune disorders.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo TMS and tDCS to explore effects on movement intention and neural activity
Neuroimaging and Data Collection
Neuroimaging recordings and data collection for hypotheses development
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Anodal tDCS of left or right AG or FC
- rTMS of left or right angular gyrus (AG) or frontal cortex (FC)
- Sham TMS3 stimulation
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor